The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2019Chaperone-mediated Autophagy to Counteract Alpha-synuclein Pathology
Study Rationale:
A hallmark of Parkinson’s disease (PD) is aggregates of the protein alpha-synuclein. One of the main pathways to remove excess amounts of alpha-synuclein, which can be toxic for the... -
Target Advancement Program, 2019Investigating Vulnerability of Subsets of Dopaminergic Neurons
Study Rationale:
Brain cells that produce the neurotransmitter dopamine are the most vulnerable to cell death in Parkinson’s disease (PD), but the reasons for this are not known. New techniques have... -
Research Grant, 2019Parkinson’s Digital Biomarker DREAM Challenges to Develop Measures of Symptoms and Severity
Study Rationale:
The use of wearable sensors to detect and measure Parkinson’s disease shows great promise. However how to convert the raw data to specific measures is poorly understood. We propose a... -
Access to Data and Biospecimens, 2019Convergence of LRRK2 and GBA in the Pathogenesis of Parkinson’s Disease Supplement
Promising Outcomes of Original Grant:
In our original project we used dopamine cells derived from induced pluripotent stem cells (iPSCs) from people with Parkinson’s-associated LRRK2 or GBA mutations... -
Research Grant, 2019Determining the Level of LRRK2 Inhibition Required for Therapeutic Efficacy
Study Rationale:
While inhibitors of LRRK2 activity are currently in clinical trials for the treatment of Parkinson’s disease, the minimum requirement of target engagement to significantly modify... -
Therapeutic Pipeline Program, 2019CRISPRi/dCas9 Downregulation of Alpha-synuclein as a Novel Gene Therapy
Study Rationale:
Neurodegeneration in the brains of people with Parkinson’s may be caused by protein clumps called Lewy bodies, the pathological hallmark of the disease. Lewy bodies consist of a...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.